Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 20-Hydroxyecdysone SCHEMBL20033388 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL9481370 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8193574 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL6243068 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8193572 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL990951 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL22087 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8861138 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8861142 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL3043993 | 1.00 | MEN1 (0.71) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542295-B2 | Use of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathies | BIOPHYTIS (FR) | 2023-01-03 | — | — | US | disclosed |
| EP-2995310-B1 | Compositions for the treatment of overtraining syndrome | SHI RES & DEVELOPMENT AB (SE) | 2021-11-03 | — | — | EP | disclosed |
| US-20200179407-A1 | USE OF 20-HYDROXYECDYSONE AND THE DERIVATIVES THEREOF IN THE TREATMENT OF MYOPATHIES | BIOPHYTIS (FR) | 2020-06-11 | — | — | US | disclosed |
| US-10316056-B2 | Chemical compounds and use thereof for improving muscular quality | BIOPHYTIS (FR) | 2019-06-11 | — | — | US | disclosed |
| US-9938315-B2 | Chemical compounds and use thereof for improving muscular quality | BIOPHYTIS (FR) | 2018-04-10 | — | — | US | disclosed |
| US-20170252389-A1 | COMPOSITIONS FOR THE TREATMENT OF OVERTRAINING SYNDROME | SHI RESEARCH & DEVELOPMENT AB (SE) | 2017-09-07 | — | — | US | disclosed |
| EP-2995310-A1 | Compositions for the treatment of overtraining syndrome | Swedish Herbal Institute Research & Development AB (SE) | 2016-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542295-B2 | Use of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathies | MUSK, MTPN, MYLK2 | MEN1 2545/4885KMT2A 2647/4885 |
| US-10316056-B2 | Chemical compounds and use thereof for improving muscular quality | CPT1B, PYGM, GYS1 | MEN1 4051/4885KMT2A 1396/4885 |
| US-20200179407-A1 | USE OF 20-HYDROXYECDYSONE AND THE DERIVATIVES THEREOF IN THE TREATMENT OF MYOPATHIES | MUSK, MTPN, MYLK2 | MEN1 2545/4885KMT2A 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.